Calls for papers
-
According to Insmed, the US FDA has lifted the clinical hold on Arikace liposomal amikacin for inhalation for the treatment of patients with non-tuberculous mycobacteria (NTM) lung disease. In October 2011, the FDA had asked… Read more . . .
-
As UK-based Prosonix transitions from a particle engineering specialist into a pharmaceutical company with three inhaled respiratory drugs in its pipeline, it has announced the appointment of Rob Crocker as its first Head of Regulatory… Read more . . .
-
Takeda Pharmaceutical has announced that it will lay off approximately 2,800 employees — 2,100 in Europe and 700 in the US — as it realigns to accommodate its 2011 acquisition of Nycomed. Nycomed’s products include… Read more . . .
-
Manufacturer Church & Dwight UK has informed the Medicines and Healthcare products Regulatory Agency (MHRA) of possible bacterial contamination of its Sterimar Isotonic 100ml saline nasal spray, which is available over the counter in the… Read more . . .
-
After the rejection of its last offer in December, Valeant Pharmaceuticals says that it has increased its offer for ISTA to $7.50 per share from $6.50 and adds that it has informed ISTA that the… Read more . . .
-
MAP Pharmaceuticals has appointed W. James O’Shea, a former President and COO of Sepracor, to its board of directors. During eight years at Sepracor, O’Shea held a number of positions in operations and commercialization and… Read more . . .
-
A new report available from BCC Research projects a compound annual growth rate (CAGR) of 14.3% for the respiratory drug delivery technologies market, meaning that the global market would approximately double to $44 billion by… Read more . . .
-
Applications due by January 31, 2012. Details of the award and submission information are avaiable on this document. The application form is available here. Applicants must work in academia or small and medium enterprises (SMEs)… Read more . . .
-
According to an interim management statement released by Vectura, the company anticipates a cut R&D expenditures by £1m for the fiscal year ending March 31 2012 and expects additional cuts for FY2013. The company said,… Read more . . .
-
Fleming Pharmaceuticals says that it sold the rights to its Ocean brand saline nasal products, along with three other products, to Valeant, which will distribute the product through Valeant Pharmaceuticals North America LLC. Ocean nasal… Read more . . .
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK